Procaps Group S.A. Logo

Procaps Group S.A.

PROC

(2.0)
Stock Price

0,69 USD

7.79% ROA

97.17% ROE

6.18x PER

Market Cap.

242.571.600,00 USD

736.1% DER

0% Yield

15.38% NPM

Procaps Group S.A. Stock Analysis

Procaps Group S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Procaps Group S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (932.83%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

5 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (44), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

6 PBV

The stock's elevated P/BV ratio (7.18x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 DER

The company has a high debt to equity ratio (875%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Procaps Group S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Procaps Group S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Procaps Group S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Procaps Group S.A. Revenue
Year Revenue Growth
2019 324.792.000
2020 331.467.000 2.01%
2021 409.742.000 19.1%
2022 409.920.000 0.04%
2023 473.640.000 13.45%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Procaps Group S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2019 0
2020 0 0%
2021 3.064.000 100%
2022 2.733.000 -12.11%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Procaps Group S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 60.257.000
2020 58.631.000 -2.77%
2021 82.187.000 28.66%
2022 105.911.000 22.4%
2023 103.116.000 -2.71%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Procaps Group S.A. EBITDA
Year EBITDA Growth
2019 52.730.000
2020 76.830.000 31.37%
2021 9.822.000 -682.22%
2022 46.561.000 78.91%
2023 65.400.000 28.81%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Procaps Group S.A. Gross Profit
Year Gross Profit Growth
2019 182.498.000
2020 191.314.000 4.61%
2021 235.713.000 18.84%
2022 239.569.000 1.61%
2023 273.612.000 12.44%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Procaps Group S.A. Net Profit
Year Net Profit Growth
2019 -17.013.000
2020 -10.447.000 -62.85%
2021 -100.863.000 89.64%
2022 42.540.000 337.1%
2023 32.776.000 -29.79%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Procaps Group S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 -1 100%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Procaps Group S.A. Free Cashflow
Year Free Cashflow Growth
2019 48.588.000
2020 53.002.000 8.33%
2021 12.778.000 -314.79%
2022 -17.469.000 173.15%
2023 39.714.000 143.99%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Procaps Group S.A. Operating Cashflow
Year Operating Cashflow Growth
2019 68.286.000
2020 70.920.000 3.71%
2021 37.303.000 -90.12%
2022 14.106.000 -164.45%
2023 47.394.000 70.24%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Procaps Group S.A. Capital Expenditure
Year Capital Expenditure Growth
2019 19.698.000
2020 17.918.000 -9.93%
2021 24.525.000 26.94%
2022 31.575.000 22.33%
2023 7.680.000 -311.13%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Procaps Group S.A. Equity
Year Equity Growth
2019 -243.947.000
2020 -254.678.000 4.21%
2021 -38.340.000 -564.26%
2022 -1.878.000 -1941.53%
2023 38.454.000 104.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Procaps Group S.A. Assets
Year Assets Growth
2019 337.728.000
2020 359.538.000 6.07%
2021 462.135.000 22.2%
2022 460.187.000 -0.42%
2023 498.554.000 7.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Procaps Group S.A. Liabilities
Year Liabilities Growth
2019 581.675.000
2020 614.216.000 5.3%
2021 500.475.000 -22.73%
2022 462.065.000 -8.31%
2023 460.100.000 -0.43%

Procaps Group S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.26
Net Income per Share
0.35
Price to Earning Ratio
6.18x
Price To Sales Ratio
1.06x
POCF Ratio
3.2
PFCF Ratio
4.64
Price to Book Ratio
5.52
EV to Sales
2.25
EV Over EBITDA
9.52
EV to Operating CashFlow
7.59
EV to FreeCashFlow
9.85
Earnings Yield
0.16
FreeCashFlow Yield
0.22
Market Cap
0,24 Bil.
Enterprise Value
0,51 Bil.
Graham Number
1.75
Graham NetNet
-2.54

Income Statement Metrics

Net Income per Share
0.35
Income Quality
1.93
ROE
0.97
Return On Assets
0.07
Return On Capital Employed
0.15
Net Income per EBT
0.71
EBT Per Ebit
1.1
Ebit per Revenue
0.2
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.22
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-0.06
Gross Profit Margin
0.57
Operating Profit Margin
0.2
Pretax Profit Margin
0.22
Net Profit Margin
0.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.67
Free CashFlow per Share
0.52
Capex to Operating CashFlow
0.23
Capex to Revenue
0.07
Capex to Depreciation
1.67
Return on Invested Capital
0.1
Return on Tangible Assets
0.08
Days Sales Outstanding
272.98
Days Payables Outstanding
331.34
Days of Inventory on Hand
362.66
Receivables Turnover
1.34
Payables Turnover
1.1
Inventory Turnover
1.01
Capex per Share
0.15

Balance Sheet

Cash per Share
0,26
Book Value per Share
0,38
Tangible Book Value per Share
-0.09
Shareholders Equity per Share
0.39
Interest Debt per Share
3.08
Debt to Equity
7.36
Debt to Assets
0.58
Net Debt to EBITDA
5.04
Current Ratio
1.47
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,16 Bil.
Invested Capital
279886000
Working Capital
0,10 Bil.
Intangibles to Total Assets
0.09
Average Receivables
0,17 Bil.
Average Payables
0,09 Bil.
Average Inventory
100858500
Debt to Market Cap
1.2

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Procaps Group S.A. Dividends
Year Dividends Growth

Procaps Group S.A. Profile

About Procaps Group S.A.

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

CEO
Mr. Jose Antonio Toledo Vieira
Employee
5.500
Address
9 Rue de Bitbourg
Luxembourg City, 1273

Procaps Group S.A. Executives & BODs

Procaps Group S.A. Executives & BODs
# Name Age
1 Ms. Melissa Angelini
Investor Relations Director
70
2 Mr. Jose Antonio Toledo Vieira
Chief Executive Officer
70
3 Mr. Ruben Minski
Founder & Director
70
4 Mr. Mauricio Castaneda Caballero
Vice-President of Human Resources
70
5 Ms. Marcela Carvajalino Pagano
Vice-President of Corporate & Legal Affairs
70
6 Mr. Luis Alberto Palacios Aragon
Vice-President of International Marketing and R&D
70
7 Mr. Patricio Vargas Munoz
Global Chief Financial Officer
70
8 Dr. Camilo Camacho
Chief Operations Officer
70

Procaps Group S.A. Competitors